Serveur d'exploration COVID et hydrochloroquine - Exploration (Accueil)

Index « Keywords » - entrée « Anti-Bacterial Agents (adverse effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Anti-Bacterial Agents (administration & dosage) < Anti-Bacterial Agents (adverse effects) < Anti-Bacterial Agents (blood)  Facettes :

List of bibliographic references indexed by Anti-Bacterial Agents (adverse effects)

Number of relevant bibliographic references: 21.
[0-20] [0 - 20][0 - 21][20-20][20-40]
Ident.Authors (with country if any)Title
000042 (2021) Amaya García-Fernández [Espagne] ; Pablo Ramos-Ruiz [Espagne] ; Alicia Ibá Ez-Criado [Espagne] ; Scar Moreno-Pérez [Espagne] ; Cristina Cambra-Poveda [Espagne] ; Juan Gabriel Martínez-Martínez [Espagne]Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients.
000242 (2021) Basma S. Mansour [Égypte] ; Noha A. Salem [Égypte] ; Ghada Abdel Kader [Égypte] ; Gamal Abdel-Alrahman [Égypte] ; Omayma M. Mahmoud [Égypte]Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model.
000382 (2021) Michael Malaty [Australie] ; Tahrima Kayes [Australie] ; Anjalee T. Amarasekera [Australie] ; Matthew Kodsi [Australie] ; C Raina Macintyre [Australie] ; Timothy C. Tan [Australie]Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.
000401 (2021) Thomas F. O'Connell [États-Unis] ; Christopher J. Bradley [États-Unis] ; Amr E. Abbas [États-Unis] ; Brian D. Williamson [États-Unis] ; Akash Rusia [États-Unis] ; Adam M. Tawney [États-Unis] ; Rick Gaines [États-Unis] ; Jason Schott [États-Unis] ; Alex Dmitrienko [États-Unis] ; David E. Haines [États-Unis]Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
000527 (2021) Luigi Moschini [Italie] ; Marco Loffi [Italie] ; Valentina Regazzoni [Italie] ; Giuseppe Di Tano [Italie] ; Elisa Gherbesi [Italie] ; Gian Battista Danzi [Italie]Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection.
000604 (2021) Guillaume Hache [France] ; Jean Marc Rolain [France] ; Philippe Gautret [France] ; Jean-Claude Deharo [France] ; Philippe Brouqui [France] ; Didier Raoult [France] ; Stéphane Honoré [France]Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
000611 (2021) Mary Kelly [Irlande (pays)] ; R Isìn O'Connor [Irlande (pays)] ; Liam Townsend [Irlande (pays)] ; Miriam Coghlan [Irlande (pays)] ; Eileen Relihan [Irlande (pays)] ; Miriam Moriarty [Irlande (pays)] ; Bernard Carr [Irlande (pays)] ; Gail Melanophy [Irlande (pays)] ; Caitriona Doyle [Irlande (pays)] ; Ciaran Bannan [Irlande (pays)] ; Ruth O'Riordan [Irlande (pays)] ; Concepta Merry [Irlande (pays)] ; Susie Clarke [Irlande (pays)] ; Colm Bergin [Irlande (pays)]Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
000612 (2021) Jennifer Carron [Irlande (pays)] ; Zain Sharif [Irlande (pays)] ; Hafiz Hussein [Irlande (pays)] ; Mark Kennedy [Irlande (pays)] ; Brendan Mcadam [Irlande (pays)] ; Richard Sheahan [Irlande (pays)]Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.
000723 (2021) Andrea Bernardini [Italie] ; Giuseppe Ciconte [Italie] ; Gabriele Negro [Italie] ; Roberto Rondine [Italie] ; Valerio Mecarocci [Italie] ; Tommaso Viva [Italie] ; Francesca Santini [Italie] ; Carlo De Innocentiis [Italie] ; Luigi Giannelli [Italie] ; Ewa Witkowska [Italie] ; Emanuela Teresina Locati [Italie] ; Serenella Castelvecchio [Italie] ; Massimiliano M. Marrocco-Trischitta [Italie] ; Gabriele Vicedomini [Italie] ; Lorenzo Menicanti [Italie] ; Carlo Pappone [Italie]Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
000746 (2021) Andy On-Tik Wong [États-Unis] ; Bimal Gurung [Hong Kong] ; Wing Sum Wong [États-Unis] ; Suet Yee Mak [États-Unis] ; Wan Wai Tse [États-Unis] ; Chloe M. Li [Hong Kong] ; Deborah K. Lieu [États-Unis] ; Kevin D. Costa [États-Unis] ; Ronald A. Li [États-Unis] ; Roger J. Hajjar [États-Unis]Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues.
000766 (2021) Vakaramoko Diaby [États-Unis] ; Reem D. Almutairi [États-Unis] ; Ziyan Chen [États-Unis] ; Richard K. Moussa ; Abdrahmane Berthe [Canada]A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
000C94 (2020) Yves-Marie Pers [France] ; Guillaume Padern [France]Revisiting the cardiovascular risk of hydroxychloroquine in RA.
000D93 (2020) Tan Chen Wu [Brésil] ; Luciana Sacilotto [Brésil] ; Francisco Carlos Da Costa Darrieux [Brésil] ; Cristiano Faria Pisani [Brésil] ; Sissy Lara De Melo [Brésil] ; Denise Tessariol Hachul [Brésil] ; Mauricio Scanavacca [Brésil]QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
000E10 (2020) Pradeesh Sivapalan [Danemark] ; Charlotte Suppli Ulrik [Danemark] ; Therese Sophie Lappere [Danemark] ; Josefin Viktoria Eklöf [Danemark] ; Saher Burhan Shaker [Danemark] ; Uffe Christian Steinholtz B Dtger [Danemark] ; Andrea Browatzki [Danemark] ; Christian Niels Meyer [Danemark] ; Ulla M Ller Weinreich [Danemark] ; Christian B. Laursen [Danemark] ; Tor Biering-S Rensen [Danemark] ; Filip Krag Knop [Danemark] ; Jens D. Lundgren [Danemark] ; Jens-Ulrik St Hr Jensen [Danemark]Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.
001036 (2020) Avni Uygar Seyhan [Turquie] ; Fatih Doganay [Turquie] ; Erdal Yilmaz [Turquie] ; Nurdan Papila Topal [Turquie] ; Rohat Ak [Turquie]Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
001232 (2020) Bruno Mégarbane [France] ; Jean-Michel Scherrmann [France]Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
001374 (2020) Moussa Saleh ; James Gabriels ; David Chang ; Beom Soo Kim ; Amtul Mansoor ; Eitezaz Mahmood ; Parth Makker ; Haisam Ismail ; Bruce Goldner ; Jonathan Willner ; Stuart Beldner ; Raman Mitra ; Roy John ; Jason Chinitz ; Nicholas Skipitaris ; Stavros Mountantonakis ; Laurence M. EpsteinEffect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
001517 (2020) Dan M. Roden ; Robert A. Harrington ; Athena Poppas ; Andrea M. RussoConsiderations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment.
001682 (2020) Niyada Naksuk [États-Unis] ; Sorin Lazar [États-Unis] ; Thoetchai Bee Peeraphatdit [États-Unis]Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
001881 (2020) Lauren S. Ranard [États-Unis] ; Justin A. Fried [États-Unis] ; Marwah Abdalla [États-Unis] ; D Edmund Anstey [États-Unis] ; Raymond C. Givens [États-Unis] ; Deepa Kumaraiah [États-Unis] ; Susheel K. Kodali [États-Unis] ; Koji Takeda [États-Unis] ; Dimitrios Karmpaliotis [États-Unis] ; Leroy E. Rabbani [États-Unis] ; Gabriel Sayer [États-Unis] ; Ajay J. Kirtane [États-Unis] ; Martin B. Leon [États-Unis] ; Allan Schwartz [États-Unis] ; Nir Uriel [États-Unis] ; Amirali Masoumi [États-Unis]Approach to Acute Cardiovascular Complications in COVID-19 Infection.
001957 (2020) Juan Jiménez-Jáimez [Espagne] ; Rosa Macías-Ruiz [Espagne] ; Francisco Bermúdez-Jiménez [Espagne] ; Ricardo Rubini-Costa [Espagne] ; Jessica Ramírez-Taboada [Espagne] ; Paula Isabel García Flores [Espagne] ; Laura Gallo-Padilla [Espagne] ; Juan Diego Mediavilla García [Espagne] ; Concepci N Morales García [Espagne] ; Sara Moreno Suárez [Espagne] ; Celia Fignani Molina [Espagne] ; Miguel Lvarez L Pez [Espagne] ; Luis Tercedor [Espagne]Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Anti-Bacterial Agents (adverse effects)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Anti-Bacterial Agents (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Anti-Bacterial Agents (adverse effects)
}}

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021